Roche, Viking, and Syntis showcase obesity drug candidates
A flurry of clinical readouts for new weight-loss therapies has seen Roche, Viking, and Syntis all showing off new drug candidates.
Roche's IgAN hopeful sefaxersen passes phase 3 test
Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.
Amgen's Horizon buyout delivers Sjögren's disease win
Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.
Pharma leaders urge Europe to halt 'slow agony' of decline
Europe's top pharma firms have called on governments to take action to change the region's story from one of decay to one of "renewal and resilience."
UK issues £45m funding call for research partnerships
The NIHR has revealed the first £45m in funding for projects that can bridge the translation gap in healthcare, focusing initially on community care.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
PMi Awards 2026 – The Winners and Highlights
Avalere Health is the night’s most awarded agency - Novo Nordisk, Roche, and The Urology Foundation top the client leaderboard
RNA-Targeted Small Molecules: From Discovery to Clinic
Leading pharma, biotech and academic experts discuss the future of RNA therapeutics.
Novel CNS Biomarkers Summit Europe
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation
Who's Speaking at the DIA-MHRA Global Summit 2026?
See who's speaking when regulators and industry convene at the DIA-MHRA Global Summit
4th Cell Therapy for Autoimmune Disease Summit
Developers are racing to overcome challenges around safety, scalability, durability of response, and patient access